re: Ann: Clinuvel commences US Phase III tria... It's about as safe a bet for approval in Europe as you're going to get except for a drug that is attempting to get generic approval.
The downside is:
1 - we don't know when European regulators will make a decision
2 - the market still doesn't appear to be too jazzed about EPP
3 - if the overall markets get slammed by the stuff going on in Europe (Greece, etc.), then Australian markets will suffer as well
4 - the company's cash position, which I still suspect is keeping a lot of people on the sidelines
JMO
Ann: Clinuvel commences US Phase III trial of SCE, page-9
Add CUV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$13.28 |
Change
-0.250(1.85%) |
Mkt cap ! $664.8M | |||
| Open | High | Low | Value | Volume |
| $13.55 | $13.62 | $13.25 | $1.157M | 86.45K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 227 | $13.28 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $13.42 | 228 | 1 |
View Market Depth
| Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
| CUV (ASX) Chart |